Clinical trials: Bladder Cancer Recurrence
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Bladder Cancer
Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer
Disease recurrence and progression is a major issue in high risk non-muscle-invasive bladder cancer (NMIBC). The current study compares two adjuvant instillation therapies in the treatment of high risk NMIBC.
- Trial name
- FB10 (NCT03664869)
- Testing
- BCG instillation therapy, Sequential BCG and EMDA mitomycin C
- Where
- 7 sites in Finland
- Volunteers
- 300 people
- Sponsor
- Turku University Hospital
Bladder Cancer
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers
Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy of immune system stimulation is the determinant factor for patient response to BCG.
- Trial name
- NCT04723121
- Testing
- Urine ELISA for immunological markers (IL-2 and IL-10), Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis
- Where
- Egypt
- Volunteers
- 204 people
- Sponsor
- Mansoura University
Bladder Cancer
The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor.
The Xpert BC Monitor is an mRNA-based urinary marker test for BC surveillance which measures the levels of five target mRNAs (ABL1, ANXA10, UPK1B, CRH and IGF2) from a voided urine sample by real-time RT-PCR.
- Trial name
- NCT04603612
- Testing
- Primary TURBT
- Where
- Egypt
- Volunteers
- 254 people
- Sponsor
- Mansoura University
Carcinoma, Transitional Cell, Bladder Cancer
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer.
- Conditions
- Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
- Trial name
- NCT00722553
- Testing
- Pralatrexate Injection, Vitamin B12, Folic Acid
- Where
- 19 sites in United States, Argentina and 4 more
- Volunteers
- 30 people
- Sponsor
- Acrotech Biopharma Inc.
Bladder Cancer
Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study
The primary objective of this prospective, single-centre study is to establish the clinical performance characteristics of Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems in comparison to the methods currently…
- Trial name
- NCT03715660
- Testing
- Xpert bladder cancer monitor
- Where
- Egypt
- Volunteers
- 198 people
- Sponsor
- Mansoura University
Bladder Cancer
Prospective Collection of Samples for Urothelial Cancer of Bladder
ProCSUCaB (Prospective Collection of Samples for Urothelial Cancer of Bladder) is a monocentric, non-interventional, prospective registry that will recruit newly diagnosed intermediate- and high-risk NMIBC patients in a tertiary…
- Trial name
- ProCSUCaB (NCT04167332)
- Volunteers
- 630 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Bladder Cancer, Bladder Urothelial Carcinoma
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy
In view of sparse data of precise definition, risk factors, natural history and management of bladder perforation following Transurethral resection of bladder tumour (TURBT).
- Conditions
- Bladder Cancer, Bladder Urothelial Carcinoma, Trauma, Injuries
- Trial name
- TURBT-BP (NCT04129606)
- Testing
- Computed tomographic cystography
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Abdelwahab Hashem
Bladder Cancer, Recurrence
Photodynamic Diagnosis (PDD) in Flexible Cystoscopy
Photodynamic diagnostic (PDD) is a technique where a photodynamic drug is installed preoperatively in the bladder. Mucosa cells with a higher metabolism than normal urothelial cells, e.g.
- Conditions
- Bladder Cancer, Recurrence, PDD
- Trial name
- DaBlaCa-11 (NCT02660190)
- Testing
- hexaminoavolunate, WL cystoscopy
- Where
- 2 sites in Denmark
- Volunteers
- 696 people
- Sponsor
- Jørgen Bjerggaard Jensen
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
This pilot trial studies how well nanoparticle albumin-bound rapamycin works in treating patients with cancer that as has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced…
- Conditions
- Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm
- Trial name
- NCT02646319
- Testing
- Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Assessment of BladderLight SurvEILlance
Is BladderLight® (BL) urine testing accurate, as a non-invasive method, to exclude presence of bladder cancer in patients.
- Trial name
- ABSEIL (NCT03427034)
- Testing
- BladderLight®
- Volunteers
- 2,100 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Non Muscle Invasive Bladder Cancer
Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging
To date, fluorescence and narrow band imaging cystoscopy have been tested in many prospective within patient trials but only as an "add on" procedure.
- Trial name
- NCT01004211
- Testing
- Narrow band imaging transurethral resection, Standard transurethral resection
- Where
- 2 sites in Italy
- Volunteers
- 188 people
- Sponsor
- Paolo Puppo
Upper Tract Urothelial Carcinoma, Bladder Recurrence
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients
This clinical trial is designed to evaluate the efficacy of single immediate intravesical chemotherapy instillation in the prevention of bladder recurrence after diagnostic ureteroscopy for upper tract urothelial carcinoma (UTUC)…
- Trial name
- NCT02740426
- Testing
- Pirarubicin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Bladder Cancer, Disease Progression
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive…
- Conditions
- Bladder Cancer, Disease Progression, Recurrent Bladder Cancer
- Trial name
- NCT03174912
- Testing
- Intravesical BCG instillation
- Volunteers
- 400 people
- Sponsor
- Ankara Training and Research Hospital
Bladder Urothelial Carcinoma, TURBT
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
Compare the therapeutic utility of SPIES assisted TURB with WLI assisted TURB in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, TURBT, Bladder Neoplasm, Cystoscopy
- Trial name
- NCT03138824
- Testing
- SPIES assisted TURBT, WLI assisted TURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Oncology, Bladder Cancer
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high…
- Conditions
- Oncology, Bladder Cancer, Superficial Bladder Cancer, Recurrence
- Trial name
- NCT03121768
- Where
- Egypt
- Volunteers
- 761 people
- Sponsor
- Mansoura University
Bladder Cancer
Markers of Response to Intravesical Bladder Cancer Therapy
The goal of this laboratory research study is to see if researchers can predict whose cancer will stay in remission and whose will return in patients receiving treatment for bladder cancer.
- Trial name
- NCT01007058
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Recurrence, Upper Tract Urothelial Carcinoma
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients
This clinical trial is designed to evaluate the efficacy of single immediate intravesical chemotherapy instillation in the prevention of bladder recurrence after nephroureterectomy for primary upper tract urothelial carcinoma…
- Conditions
- Bladder Recurrence, Upper Tract Urothelial Carcinoma, Nephroureterectomy
- Trial name
- NCT02923557
- Testing
- Pirarubicin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital